NCT06646627View on ClinicalTrials.gov

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Ovarian Cancer
Interventions
DRUG

B7-H3CART

"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER